Co-Authors
This is a "connection" page, showing publications co-authored by Bruce Brockstein and Everett E. Vokes.
Connection Strength
1.873
-
Head and neck cancer in 2010: Maximizing survival and minimizing toxicity. Nat Rev Clin Oncol. 2011 Feb; 8(2):72-4.
Score: 0.384
-
Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries. Nat Rev Clin Oncol. 2010 Nov; 7(11):616-8.
Score: 0.377
-
Concurrent chemoradiotherapy for head and neck cancer. Semin Oncol. 2004 Dec; 31(6):786-93.
Score: 0.250
-
Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968.
Score: 0.127
-
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
Score: 0.122
-
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
Score: 0.092
-
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44.
Score: 0.070
-
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24.
Score: 0.067
-
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55.
Score: 0.060
-
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004 Mar 15; 10(6):1956-62.
Score: 0.060
-
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
Score: 0.058
-
Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5.
Score: 0.058
-
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
Score: 0.056
-
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
Score: 0.055
-
A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Qual Life Res. 2007 Dec; 16(10):1615-26.
Score: 0.019
-
Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck. 2006 Jan; 28(1):64-73.
Score: 0.017